Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Authors:
- on behalf of the SOLE InvestigatorsOIon behalf of the SOLE Investigators
- Stefan AebiSAStefan Aebi
Open Access
- 10 April 2019
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 120 (10) , 959-967
Abstract
Background In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Intermittent therapy with 3-month breaks may be beneficial for patients’ quality of life (QoL). Methods In the SOLE QoL sub-study, 956 patients completed the Breast Cancer Prevention Trial (BCPT) symptom and further QoL scales up to 24 months after randomisation. Differences in change of QoL from baseline between the two administration schedules were tested at 12 and 24 months using repeated measures mixed-models. The primary outcome was change in hot flushes at 12 months. Results There was no difference in hot flushes at 12 months between the two schedules, but patients receiving intermittent letrozole reported significantly more improvement at 24 months. They also indicated less worsening in vaginal problems, musculoskeletal pain, sleep disturbance, physical well-being and mood at 12 months. Overall, 25–30% of patients reported a clinically relevant worsening in key symptoms and global QoL. Conclusion Less symptom worsening was observed during the first year of extended treatment with the intermittent administration. For women experiencing an increased symptom burden of extended adjuvant endocrine therapy, an intermittent administration is a safe alternative. Clinical trial information Clinical trial information: NCT00553410.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 26 references indexed in Scilit:
- Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisationBritish Journal of Cancer, 2012
- Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapyPsycho-Oncology, 2011
- Stopping Treatment Can Reverse Acquired Resistance to LetrozoleCancer Research, 2008
- Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife womenBreast Cancer Research and Treatment, 2007
- Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients—The International Breast Cancer Study Group Trial VIIIJournal of Clinical Oncology, 2007
- Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast CancerBreast Cancer Research and Treatment, 2006
- Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal WomenJournal of Clinical Oncology, 2005
- The BCPT Symptom Scales: A Measure of Physical Symptoms for Women Diagnosed With or at Risk for Breast CancerJNCI: Journal of the National Cancer Institute, 2005
- Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical TrialsJournal of Biopharmaceutical Statistics, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003